Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 6/20 | 0.49 |
| ▸ | KDR | P35968 | 6/20 | 0.49 |
| ▸ | IKBKB | O14920 | 6/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15907244 | 0.83 | NPC1 (0.40) | KDRRAB9APOLBSMN1; SMN2KDM4E | |
| SCHEMBL18323148 | 0.80 | GRM5 (0.41) | PDGFRBKDRIKBKBPTPN11RAB9A | |
| SCHEMBL15907241 | 0.79 | PLAU (0.39) | KDRRAB9APOLBSMN1; SMN2KDM4E | |
| SCHEMBL15907238 | 0.76 | KMT2A (0.45) | RAB9APOLBKDM4E | |
| SCHEMBL15907246 | 0.76 | GAA (0.37) | PDGFRBKDRPTPN11RAB9ALMNA | |
| SCHEMBL15907158 | 0.74 | KIT (0.55) | — | |
| SCHEMBL15907253 | 0.74 | BCAT2 (0.45) | PDGFRBKDRIKBKBRAB9ASMN1; SMN2 | |
| SCHEMBL15907242 | 0.74 | RAB9A (0.39) | RAB9APOLBSMN1; SMN2KDM4EGAA | |
| SCHEMBL18323145 | 0.73 | ALDH1A1 (0.47) | PDGFRBKDRIKBKBRAB9APOLB | |
| SCHEMBL15907302 | 0.71 | IKBKB (0.46) | PDGFRBKDRIKBKBRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | PDGFRB 831/4885KDR 676/4885IKBKB 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.